Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rune Viig Overgaard

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmaceutical Research|September 30, 2006
PKPD model of interleukin-21 effects on thermoregulation in monkeys--application and evaluation of stochastic differential equationsRune Viig Overgaard, Nick Holford, Klaus A Rytved, et al.
Plos Computational Biology|October 25, 2011
An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancersMoran Elishmereni, Yuri Kheifetz, Henrik Søndergaard, et al.
Clinical Pharmacokinetics|April 20, 2018
Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I TrialsRasmus Vestergaard Juul, Michael Højby Rasmussen, Henrik Agersø, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2020
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly SomapacitanRasmus Juul Kildemoes, Michael Højby Rasmussen, Henrik Agersø, et al.
Diabetes, Obesity & Metabolism|February 4, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approachTheodoros Papathanasiou, Anders Strathe, Henrik Agersø, et al.
Diabetes, Obesity & Metabolism|June 24, 2026
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based TherapiesRune Viig Overgaard, Henrik Agersø, Christian Hollensen, et al.
The AAPS Journal|April 25, 2018
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug CombinationsTheodoros Papathanasiou, Anders Strathe, Andrew C Hooker, et al.
Computer Methods and Programs in Biomedicine|March 10, 2009
Population stochastic modelling (PSM)--an R package for mixed-effects models based on stochastic differential equationsSøren Klim, Stig Bousgaard Mortensen, Niels Rode Kristensen, et al.
Advances in Therapy|March 10, 2015
Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritisMia Sandberg Lundblad, Rune Viig Overgaard, Marie Göthberg, et al.
The AAPS Journal|July 31, 2019
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response ModelsTheodoros Papathanasiou, Anders Strathe, Rune Viig Overgaard, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmaceutical Research|September 30, 2006
PKPD model of interleukin-21 effects on thermoregulation in monkeys--application and evaluation of stochastic differential equationsRune Viig Overgaard, Nick Holford, Klaus A Rytved, et al.
Plos Computational Biology|October 25, 2011
An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancersMoran Elishmereni, Yuri Kheifetz, Henrik Søndergaard, et al.
Clinical Pharmacokinetics|April 20, 2018
Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I TrialsRasmus Vestergaard Juul, Michael Højby Rasmussen, Henrik Agersø, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2020
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly SomapacitanRasmus Juul Kildemoes, Michael Højby Rasmussen, Henrik Agersø, et al.
Diabetes, Obesity & Metabolism|February 4, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approachTheodoros Papathanasiou, Anders Strathe, Henrik Agersø, et al.
Diabetes, Obesity & Metabolism|June 24, 2026
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based TherapiesRune Viig Overgaard, Henrik Agersø, Christian Hollensen, et al.
The AAPS Journal|April 25, 2018
Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug CombinationsTheodoros Papathanasiou, Anders Strathe, Andrew C Hooker, et al.
Computer Methods and Programs in Biomedicine|March 10, 2009
Population stochastic modelling (PSM)--an R package for mixed-effects models based on stochastic differential equationsSøren Klim, Stig Bousgaard Mortensen, Niels Rode Kristensen, et al.
Advances in Therapy|March 10, 2015
Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritisMia Sandberg Lundblad, Rune Viig Overgaard, Marie Göthberg, et al.
The AAPS Journal|July 31, 2019
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response ModelsTheodoros Papathanasiou, Anders Strathe, Rune Viig Overgaard, et al.
Pageof 2